Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CASP3 | P42574 | 3/20 | 0.53 |
| ▸ | MDM4 | O15151 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | FABP7 | O15540 | 1/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29620331 | 1.00 | KMT2A (0.53) | KMT2ACASP3MDM4TP53ATM | |
| SCHEMBL29400606 | 1.00 | KMT2A (0.53) | KMT2ACASP3MDM4TP53ATM | |
| SCHEMBL30851468 | 1.00 | KMT2A (0.53) | KMT2ACASP3MDM4TP53ATM | |
| SCHEMBL29620335 | 1.00 | KMT2A (0.53) | KMT2ACASP3MDM4TP53ATM | |
| SCHEMBL118281 | 1.00 | KMT2A (0.53) | KMT2ACASP3MDM4TP53ATM | |
| SCHEMBL29401270 | 1.00 | KMT2A (0.53) | KMT2ACASP3MDM4TP53ATM | |
| SCHEMBL29384904 | 1.00 | KMT2A (0.53) | KMT2ACASP3MDM4TP53ATM | |
| SCHEMBL2307241 | 1.00 | KMT2A (0.53) | KMT2ACASP3MDM4TP53ATM | |
| SCHEMBL6507736 | 0.92 | KMT2A (0.52) | KMT2ACASP3MDM4TP53ATM | |
| SCHEMBL31734716 | 0.92 | KMT2A (0.52) | KMT2ACASP3MDM4TP53ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4289425-A2 | NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS | Tseng, Yufeng, Jane (US) | 2023-12-13 | — | — | EP | claimed |
| US-20230018423-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | YODA THERAPEUTICS INC. (TW) | 2023-01-19 | — | — | US | claimed |
| EP-4108240-A2 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | Yoda Pharmaceuticals Inc. (KY) | 2022-12-28 | — | — | EP | claimed |
| US-20200361894-A1 | NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS | NATIONAL YANG MING CHIAO TUNG UNIVERSITY (TW) | 2020-11-19 | — | — | US | claimed |
| EP-3512840-A1 | NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS | Tseng, Yufeng, Jane (US) | 2019-07-24 | — | — | EP | claimed |
| WO-2018053161-A1 | NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS | NATIONAL TAIWAN UNIVERSITY (TW) | 2018-03-22 | — | — | WO | claimed |
| EP-3512840-B1 | NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS | TSENG YUFENG JANE (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-4289425-A2 | NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS | Tseng, Yufeng, Jane (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-115989341-A | Method for manufacturing structure with conductive pattern | 旭化成株式会社 | 2023-04-18 | — | — | CN | disclosed |
| CN-115968113-A | Method for manufacturing structure with conductive pattern, kit and system | 旭化成株式会社 | 2023-04-14 | — | — | CN | disclosed |
| EP-4108240-A2 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | Yoda Pharmaceuticals Inc. (KY) | 2022-12-28 | — | — | EP | disclosed |
| US-11370775-B2 | Substituted benzimidazole derivatives as D-amino acid oxidase (DAAO) inhibitors | Tseng, Yufeng Jane (US) | 2022-06-28 | — | — | US | disclosed |
| US-11149066-B2 | Thrombospondin 1-binding peptide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-10-19 | — | — | US | disclosed |
| WO-2008080223-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-10 | — | — | WO | disclosed |
| EP-1910279-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2008-04-16 | — | — | EP | disclosed |
| WO-2008042480-A2 | EPOXIDE INHIBITORS OF CYSTEINE PROTEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2008-04-10 | — | — | WO | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| WO-2007002639-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-04 | — | — | WO | disclosed |
| US-6372883-B1 | FOR THERAPY AND PROPHYLAXIS OF INFECTIONS CAUSED BY HEPATITIS C, HEPATITIS G AND HUMAN GB VIRUSES | HOFFMANN-LA ROCHE INC. | 2002-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149066-B2 | Thrombospondin 1-binding peptide | SERPINC1, TEK, ARGLU1 | KMT2A 4374/4885CASP3 2291/4885MDM4 3675/4885 |
| US-20230018423-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | NLRP3, NOD1, NLRP1 | KMT2A 4102/4885CASP3 58/4885MDM4 3214/4885 |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | KMT2A 3406/4885CASP3 760/4885MDM4 934/4885 |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | GALE, ENGASE, UGGT1 | KMT2A 1219/4885CASP3 2910/4885MDM4 1166/4885 |
| US-11370775-B2 | Substituted benzimidazole derivatives as D-amino acid oxidase (DAAO) inhibitors | DAO, DDO, IL4I1 | KMT2A 1384/4885CASP3 888/4885MDM4 4557/4885 |
| US-20200361894-A1 | NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS | DAO, DDO, DDC | KMT2A 943/4885CASP3 695/4885MDM4 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.